-
Products are supplied strictly for laboratory and scientific research — not for human or veterinary use.
Research & Education
GLP-1 hair loss is frequently discussed online. Hair loss appears in current weight-management product labeling, but the reason can be difficult to determine because substantial weight change, nutrition, illness, stress, hormones and other medicines can also affect hair cycling.
Current Zepbound labeling lists hair loss among common adverse reactions reported in clinical trials. Wegovy labeling also reports hair-loss events in weight-management studies. A listed adverse event means it was observed; it does not always prove a direct biological cause.
Rapid or substantial weight loss can coincide with diffuse shedding known clinically as telogen effluvium. Reduced intake of energy, protein or micronutrients may also be relevant. These possibilities should be assessed rather than assuming every case has one cause.
A clinician may ask about timing, pattern, recent weight trajectory, diet, illness, pregnancy, thyroid symptoms, family history and other medicines. Depending on findings, examination or laboratory testing may be appropriate.
Spontaneous reports and social-media accounts are useful for generating safety questions but usually lack an untreated comparison group and complete medical information. Randomized trials and post-marketing surveillance provide stronger—but still imperfect—evidence.
Only the prescribing clinician can weigh severity, other causes, benefits and risks. Do not change a prescription without guidance.
No. Products and trials differ, so rates should come from the current product-specific label.
No. Unnecessary supplementation can create risks and may delay diagnosis of another cause.
